All data are based on the daily closing price as of October 24, 2025
a

Alar Pharmaceuticals

6785.TWO
8.80 USD
-0.61
-6.48%

Overview

Last close
8.80 usd
Market cap
587.68M usd
52 week high
9.63 usd
52 week low
3.40 usd
Target price
9.41 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
2560.5093
Price/Book Value
7.6951
Enterprise Value
534.55M usd
EV/Revenue
2330.9955
EV/EBITDA
413.1064

Key financials

Revenue TTM
229322.09 usd
Gross Profit TTM
152221.86 usd
EBITDA TTM
-2.66M usd
Earnings per Share
-0.01 usd
Dividend
0.01 usd
Total assets
78.46M usd
Net debt
-20.81M usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
  • Symbol
    6785.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Yung-Shun Wen Ph.D.
  • Headquarter
    Taichung
  • Web site
    https://www.alarpharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top